HOME > REGULATORY
REGULATORY
- As Curtain Rises on Diet, MHLW Aims to Get Amended PMD Bill Enacted in Early November
October 7, 2019
- PMDA Reviewing Safety Risks for Takecab Products and More
October 7, 2019
- MOF Panel Kicks Off FY2020 Budget Debate, Prods Discussions on “Benefits and Burdens”
October 4, 2019
- MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
October 3, 2019
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- MHLW Panel Members Call for Discussion on Range of Health Coverage
September 30, 2019
- Rotavirus Vaccines Added to Public Vaccination Programs from Oct. 1, 2020: MHLW Panel
September 30, 2019
- Chuikyo Supports Earlier Price Cuts for Certain Off-Patent Brand-Name Drugs
September 26, 2019
- MHLW Orders Label Revisions for Actemra, Tagrisso, Olumiant and More
September 25, 2019
- Intussusception Cases within 21 Days after Rotavirus Vaccination Should Be Reported: MHLW Panels
September 25, 2019
- Japan Launches Panel to Discuss “Social Security for All Generations”
September 24, 2019
- Japan Approves Astellas’ HIF-PH Inhibitor, AbbVie’s Venclexta, Tecentriq’s Breast Cancer Use and More
September 24, 2019
- Japan Clears First Biosimilars for Nesp and Forteo, Second Rituxan, Avastin Follow-Ons Too
September 24, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
- Sakigake Status Withdrawn for Aducanumab: MHLW
September 20, 2019
- Kobe Univ. Received Pilot Certification as APEC Training Center of Excellence
September 20, 2019
- Doctor, Payer Reps Stress Need for More Education about Biosimilars Before Introducing Premium for Their Use: Chuikyo
September 19, 2019
- MHLW Panel Backs Inclusion of Rotavirus Vaccines to Public Immunization Program
September 17, 2019
- Orphan Status Granted to Satralizumab, 2 Other Drugs
September 17, 2019
- Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
